What is Oramed Pharmaceuticals Inc. (ORMP)?

Oramed Pharmaceuticals Inc. (ORMP) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ORMP?

The current price of ORMP is $4.16. Prices are updated in real time on Stocks360.

What is ORMP's price-to-earnings (PE) ratio?

ORMP's trailing twelve-month PE ratio is 0.98, based on current price and earnings per share data available on Stocks360.

What is ORMP's market capitalization?

ORMP's market capitalization is $173,044,993.00, placing it in the small-cap tier.

Does ORMP pay a dividend?

Yes. ORMP has a trailing twelve-month dividend yield of 0.06%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Oramed Pharmaceuticals Inc. (ORMP)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.16

Market Cap

$173.04M

PE (TTM)

0.98

EPS (TTM)

N/A

Dividend Yield

6.01%

Beta

1.28

Day Range

$4.10 – $4.17

52-wk Range

$2.09 – $5.47

Avg Volume

N/A

Volume

55.70K

Oramed Pharmaceuticals Inc. (ORMP) is a publicly traded company in the Healthcare sector. Latest price: $4.16. Market cap $173.04M. Trailing PE 0.98. Dividend yield 6.01%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $2.37 2026-10-28 · $4.16 (+75.53%)

Earnings

Most Recent

Aug 10, 2026

EPS $2.76 vs est. $0.43

Beat by $2.33

Next Earnings

Nov 12, 2026

EPS estimate $0.43

Proprietary Signals

Signal snapshot temporarily unavailable.

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	0.98×
P/S (TTM)	0.00×
P/B	0.54×
PEG	0.00×
P/FCF (TTM)	-32.20×
EV / EBITDA	1.04×
EV / Sales	0.00×
Earnings Yield	102.43%
Free Cash Flow Yield	-3.11%
Dividend Yield	6.01%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$158.53M
Net Income (TTM)	$177.24M
Free Cash Flow (TTM)	-$5.37M
Net Debt	-$14.51M
Working Capital	$42.68M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	72.96%
Return on Invested Capital	-3.21%